Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Pharmacally

Disease & Drugs

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Disease & Drugs

1,785 stories · every one Fact-Checked
Scientific illustration of immunotherapy research for extensive-stage small cell lung cancer, reflecting the evaluation of serplulimab in the ASTRIDE study.Clinical TrialsHenlius Reports Longer Overall Survival With Serplulimab in ES-SCLCHenlius reported numerical overall survival differences favoring serplulimab over atezolizumab in the US ASTRIDE study in extensive-stage small cell lung cancer.27 Oct 2026 · 4 min read
Fact-Checked
Pimicotinib demonstrates durable tumor responses and sustained joint function improvements in tenosynovial giant cell tumorClinical TrialsMerck KGaA Reports Durable Tumor Control With Pimicotinib at Two YearsMerck KGaA reported two-year results from the Phase 3 MANEUVER study of pimicotinib in tenosynovial giant cell tumor (TGCT), showing a 76.2% RECIST response rate alongside sustained improvements…27 Oct 2026 · 4 min read
Fact-Checked
Enhertu trastuzumab deruxtecan EU approval for HER2-positive early breast cancer with residual invasive diseaseNew Drug ApprovalAstraZeneca’s Enhertu Wins EU Approval in Early Breast CancerThe European Commission has approved AstraZeneca and Daiichi Sankyo’s Enhertu for adults with HER2-positive early breast cancer and residual invasive disease after neoadjuvant treatment.27 Oct 2026 · 3 min read
Fact-Checked
Scientific illustration of investigational HER2 inhibitor IAM1363 targeting HER2-driven cancers, including brain metastasesClinical TrialsIambic’s IAM1363 Shows Early Activity Against Brain MetastasesIambic Therapeutics presented updated Phase 1/1b data for investigational HER2 inhibitor IAM1363 at ESMO 2026, reporting systemic and intracranial responses in heavily pretreated patients.27 Oct 2026 · 4 min read
Fact-Checked
Pfizer TALZENNA plus XTANDI combination for HRR-mutated metastatic hormone-sensitive prostate cancerNew Drug ApprovalFDA Approves Pfizer’s TALZENNA Plus XTANDI for HRR-Mutated mHSPCPfizer’s TALZENNA plus XTANDI has received FDA approval for HRR-mutated metastatic hormone-sensitive prostate cancer.27 Oct 2026 · 4 min read
Fact-Checked
Investigational KRAS G12D inhibition and TGFβR2-PD-1 targeting strategies in pancreatic and colorectal cancerClinical TrialsIncyte Reports Strong Responses with KRAS G12D and TGFβR2×PD-1 TherapiesIncyte reported preliminary Phase 1 clinical activity for INCB161734 in KRAS G12D-mutated pancreatic and colorectal cancers and INCA33890 in advanced colorectal cancer.27 Oct 2026 · 4 min read
Fact-Checked
Illustration of heterotopic ossification and reduced bone lesion volume in children with fibrodysplasia ossificans progressiva treated with zilurgisertib.Clinical TrialsMirum Reports Positive Zilurgisertib Results in Children With FOPMirum Pharmaceuticals reported Phase 2 PROGRESS Cohort 2 results showing reduced heterotopic ossification lesion volume and improved joint mobility with zilurgisertib in children aged 6 to under 12…26 Oct 2026 · 4 min read
Fact-Checked
Corcept's Phase 2 BELLA trial evaluating relacorilant, nab-paclitaxel and bevacizumab in platinum-resistant ovarian cancerClinical TrialsCorcept Reports Positive BELLA Results for Lifyorli TripletCorcept reports a 59% response rate and 7.2-month median PFS with Lifyorli, nab-paclitaxel and bevacizumab in Phase 2 BELLA.26 Oct 2026 · 4 min read
Fact-Checked
Medical illustration of prostate cancer treatment research evaluating apalutamide plus androgen deprivation therapy before and after prostate surgery.Clinical TrialsJ&J Reports 62% EFS Risk Reduction With ERLEADA Plus ADTJohnson & Johnson reports that perioperative ERLEADA (apalutamide) plus androgen deprivation therapy reduced the hazard of event-free survival events by 62% versus surgery alone in high-risk localized or…26 Oct 2026 · 4 min read
Fact-Checked
Illustration of immune checkpoint inhibition targeting locally advanced mismatch repair-deficient colon cancer with botensilimab and balstilimab.Clinical TrialsAgenus Reports 72% Complete Response with BOT+BAL in dMMR Colon CancerAgenus reported a 72% pathologic complete response rate and an 83% major pathologic response rate after six weeks of neoadjuvant botensilimab plus balstilimab in 18 patients with locally…26 Oct 2026 · 4 min read
Fact-Checked
Scientific illustration of a CLDN18.2-targeted antibody-drug conjugate delivering a cytotoxic payload to gastric cancer cellsClinical TrialsAstraZeneca’s Sonesitatug Vedotin Meets OS but Misses PFS EndpointAstraZeneca’s Phase III CLARITY-Gastric01 trial found a significant overall-survival benefit with investigational sonesitatug vedotin in previously treated advanced CLDN18.2-positive gastric, gastroesophageal junction and oesophageal adenocarcinoma.26 Oct 2026 · 3 min read
Fact-Checked
Minimalist medical illustration of a head and neck tumour and antibody-based cancer treatment representing RYBREVANT FASPRO combination therapy.Clinical TrialsJ&J Reports Strong Tumour Responses With RYBREVANT FASPROJohnson & Johnson reported a confirmed 77% overall response rate with subcutaneous RYBREVANT FASPRO, pembrolizumab and carboplatin in a subgroup of previously untreated patients with recurrent or metastatic…26 Oct 2026 · 4 min read
Fact-Checked
Page 9 of 149